Stock ATXI AVENUE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Avenue Therapeutics, Inc.

Equities

ATXI

US05360L4032

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-06-17 EDT 		5-day change 1st Jan Change
3.56 USD -4.04% Intraday chart for Avenue Therapeutics, Inc. +5.01% -70.52%
05-16 Avenue Therapeutics, Inc Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) CI
05-15 Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
AQ
Avenue Therapeutics, Inc Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
CI
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
AQ
Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Avenue Therapeutics : Material Agreement - Form 8-K
PU
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
AQ
Avenue Therapeutics Announces Reverse Stock Split
AQ
Avenue Therapeutics to Host Virtual Key Opinion Leader Event on April 4, 2024
AQ
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
AQ
Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
AQ
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
AQ
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
AQ
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
AQ
Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy
CI
Certain Stock Options of Avenue Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.
CI
Certain Warrants of Avenue Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.
CI
Certain Common Stock of Avenue Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.
CI
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
AQ
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATXI Stock
  4. News Avenue Therapeutics, Inc.